StreetInsider.com News Articles

Form SCHEDULE 13D/A Hims & Hers Health, Inc. Filed by: Dudum Andrew

Mon, 31 Aug 2026 21:49:00 -0400

si-local-file:///var/storage/secattach/20260831/27007287.html

Hims & Hers rebrands Pilot to Hims in Australia launch

Mon, 31 Aug 2026 15:00:31 -0400

Hims & Hers Health has launched the Hims brand in Australia, rebranding Pilot, the men's health platform it acquired through its purchase of Eucalyptus earlier this year, according to a press release from the company.

Existing Pilot patients will retain their treatment plans and provider relationships under the new brand. The rebrand also extends care team availability from 12 hours a day to 24 hours a day, seven days a week.

The platform targets men's health conditions including sexual health, weight loss, and hair loss. The launch introduces new clinical pathways and treatment combinations, including options that bundle care for premature ejaculation

Hims Enters Australia, Marking First Expansion into the Asia-Pacific Market

Mon, 31 Aug 2026 15:00:00 -0400

With the rebrand of Pilot, Eucalyptus' men's health platform, Hims enters a new market, supporting its path to $1 billion in international annual revenue within the next three years

SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced it is now serving customers in Australia, marking the company's first-ever presence in the Asia-Pacific market. The entry follows Hims & Hers' acquisition of Eucalyptus earlier this year and begins with the rebrand of Pilot, Eucalyptus' men's health platform, marking the first Eucalyptus brand to

Hims Enters Australia, Marking First Expansion into the Asia-Pacific Market

Mon, 31 Aug 2026 15:00:00 -0400

With the rebrand of Pilot, Eucalyptus' men's health platform, Hims enters a new market, supporting its path to $1 billion in international annual revenue within the next three years

Hims Arrives in Australia, Bringing Personalised Care for Men Nationwide

Mon, 31 Aug 2026 15:00:00 -0400

Pilot becomes Hims, bringing innovative, personalised care to help Australian men manage sexual health, weight loss, and hair loss

SYDNEY--(BUSINESS WIRE)-- Hims & Hers, the leading global health and wellness platform, today announced it is officially launching the Hims brand in Australia and bringing its personalised care platform to men nationwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831313760/en/

The entry follows Hims & Hers' acquisition of Eucalyptus earlier this year and begins with the rebrand of

Hims Arrives in Australia, Bringing Personalised Care for Men Nationwide

Mon, 31 Aug 2026 15:00:00 -0400

Pilot becomes Hims, bringing innovative, personalised care to help Australian men manage sexual health, weight loss, and hair loss

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831313760/en/

The entry follows Hims & Hers' acquisition of Eucalyptus earlier this year and begins with the rebrand of

Form 4 Hims & Hers Health, Inc. For: Aug 25 Filed by: Dudum Andrew

Thu, 27 Aug 2026 21:02:00 -0400

si-local-file:///var/storage/secattach/20260827/26991787.html

Form 4 Hims & Hers Health, Inc. For: Aug 25 Filed by: Dudum Andrew

Thu, 27 Aug 2026 21:02:00 -0400

si-local-file:///var/storage/secattach/20260827/26991787.html

Hims and Hers (HIMS) PT Raised to $32 at Truist Securities

Tue, 25 Aug 2026 07:53:31 -0400

(Updated - August 25, 2026 7:53 AM EDT)

Truist Securities analyst Jailendra Singh raised the price target on Hims and Hers (NYSE: HIMS) to $32.00 (from $27.00) while maintaining a Hold rating.

The analyst commented: "As we incorporate incremental insights from our Truist Card Data, along with disclosures from 2Q26 earnings, we are refining our model to better delineate HIMS' revenue streams across branded GLP-1, compounded GLP-1, and non-GLP-1 businesses. While company disclosures remain limited, we intend to continue to leverage our proprietary card data to develop a more granular view of individual biz trends."

Hims and Hers (HIMS) PT Raised to $32 at Truist Securities

Tue, 25 Aug 2026 07:53:31 -0400

(Updated - August 25, 2026 7:53 AM EDT)

Truist Securities analyst Jailendra Singh raised the price target on Hims and Hers (NYSE: HIMS) to $32.00 (from $27.00) while maintaining a Hold rating.

Form 4 Hims & Hers Health, Inc. For: Aug 19 Filed by: Okupe Oluyemi

Thu, 20 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260820/26956585.html

Form 4 Hims & Hers Health, Inc. For: Aug 19 Filed by: Okupe Oluyemi

Thu, 20 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260820/26956585.html

Form 4 Hims & Hers Health, Inc. For: Aug 18 Filed by: Autor Deborah M.

Thu, 20 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260820/26956598.html

Form 4 Hims & Hers Health, Inc. For: Aug 18 Filed by: Autor Deborah M.

Thu, 20 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260820/26956598.html

Form 4 Hims & Hers Health, Inc. For: Aug 19 Filed by: Boughton Soleil

Thu, 20 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260820/26956564.html

Form 4 Hims & Hers Health, Inc. For: Aug 19 Filed by: Boughton Soleil

Thu, 20 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260820/26956564.html

Hims and Hers (HIMS) PT Lowered to $35 at Barclays

Thu, 20 Aug 2026 09:15:35 -0400

Barclays analyst Glen Santangelo lowered the price target on Hims and Hers (NYSE: HIMS) to $35.00 (from $39.00) while maintaining a Overweight rating.

The analyst comments "Model Update. We are adjusting our estimates to reflect faster revenue growth but some margin pressure from investments to support growth. We now model F26-28 revenue/EBITDA of $3,227M/$304M, $4,234 M/$457M, and $4,542M/$543M (vs $2,907M/$306M, $3,620M/$524M, and $3,850M/$588M, previously). Valuation. Shares of HIMS are currently trading at ~17x our F27E EBITDA. We are lowering our price target to $35 which is based on shares trading at ~19x (our previous $39 price target was based on ~17x).

Hims and Hers (HIMS) PT Lowered to $35 at Barclays

Thu, 20 Aug 2026 09:15:35 -0400

Barclays analyst Glen Santangelo lowered the price target on Hims and Hers (NYSE: HIMS) to $35.00 (from $39.00) while maintaining a Overweight rating.

Form 144 Hims & Hers Health, Inc. Filed by: Boughton Soleil

Wed, 19 Aug 2026 09:41:00 -0400

si-local-file:///var/storage/secattach/20260819/26948218.html

Form 144 Hims & Hers Health, Inc. Filed by: Boughton Soleil

Wed, 19 Aug 2026 09:41:00 -0400

si-local-file:///var/storage/secattach/20260819/26948218.html

Form 4 Hims & Hers Health, Inc. For: Aug 14 Filed by: Schultz Kare